Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)
Close on Nov 17, 2026Market cap $16.99MP/E –Yield –
Aligos Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Aligos Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$75.96M. For fiscal 2025 it was -$24.19M. The highest annual figure on record is -$24.19M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.19M | – |
| FY2024 | Dec 31, 2024 | -$131.21M | – |
| FY2023 | Dec 31, 2023 | -$87.68M | – |
| FY2022 | Dec 31, 2022 | -$96.05M | – |
| FY2021 | Dec 31, 2021 | -$128.33M | – |
| FY2020 | Dec 31, 2020 | -$108.54M | – |
| FY2019 | Dec 31, 2019 | -$52.26M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.04M | -153.5% |
| Q4 FY2025 | Dec 31, 2025 | -$19.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.86M | -413.4% |
| Q1 FY2025 | Mar 31, 2025 | $43.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$82.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.26M | – |
| Q2 FY2024 | Jun 30, 2024 | $5.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.42M | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.05M | – |
See a number that looks wrong?